Anoro Ellipta is a prescription medication developed by GlaxoSmithKline, a renowned pharmaceutical company committed to improving global health. It is specifically designed for individuals diagnosed with chronic obstructive pulmonary disease (COPD), a progressive lung disease that encompasses chronic bronchitis and emphysema. Anoro Ellipta combines two active ingredients, umeclidinium and vilanterol, to provide a dual-action approach to respiratory care. With its innovative Ellipta inhaler device, Anoro Ellipta delivers targeted medication for better lung function and improved breathing.

Anoro Ellipta is accompanied by an Ellipta inhaler device, designed to facilitate easy and effective medication delivery. The Ellipta device is preloaded with blister packs containing the prescribed dosage of Anoro Ellipta. With its user-friendly mechanism, the Ellipta inhaler device simplifies the inhalation process, making it convenient for individuals of varying ages and abilities to use.

As a prescription medication, Anoro Ellipta is available only through a healthcare professional. Your doctor will evaluate your respiratory condition and determine if Anoro Ellipta is suitable for your specific needs. They will prescribe the appropriate dosage strength and provide guidance on its usage.

Active Ingredients:

  1. Umeclidinium: Umeclidinium is a long-acting muscarinic antagonist (LAMA) that helps relax the muscles surrounding the airways. By blocking the action of acetylcholine, a neurotransmitter, umeclidinium promotes bronchodilation and improves airflow.
  2. Vilanterol: Vilanterol is a long-acting beta2-adrenergic agonist (LABA) that acts as a bronchodilator. It stimulates the beta2 receptors in the airway smooth muscles, leading to relaxation and widening of the airways, thereby facilitating easier breathing.

What is COPD?

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide. It is characterized by obstructed airflow to the lungs, making it increasingly difficult to breathe over time. COPD primarily encompasses two main conditions: chronic bronchitis and emphysema.

In chronic bronchitis, the airways become inflamed and produce excess mucus, leading to a persistent cough and difficulty in clearing the air passages. This results in frequent respiratory infections and a chronic cough with sputum production.

Emphysema, on the other hand, involves damage to the air sacs (alveoli) in the lungs, causing them to lose their elasticity. This leads to a reduction in the lung’s ability to exchange oxygen and carbon dioxide efficiently. As a result, individuals with emphysema experience shortness of breath, especially during physical exertion.

The primary cause of COPD is long-term exposure to harmful irritants, most commonly cigarette smoke. Other factors such as air pollution, occupational dust and chemicals, and genetic predisposition can also contribute to the development of COPD.

Symptoms of COPD often manifest gradually and worsen over time. They include persistent cough, wheezing, shortness of breath, chest tightness, and frequent respiratory infections. As COPD progresses, individuals may experience limitations in their daily activities and a reduced quality of life.

While there is no cure for COPD, early diagnosis and appropriate management can help slow its progression and improve symptoms. Treatment approaches may involve medication to alleviate symptoms, pulmonary rehabilitation programs, supplemental oxygen therapy, and lifestyle modifications such as quitting smoking and avoiding respiratory irritants.

Warnings and Precautions

These warnings and precautions are provided as general information. It is crucial to consult your healthcare professional for personalized advice, especially if you have specific medical conditions or concerns. Your doctor can evaluate your individual circumstances and determine if Anoro Ellipta is appropriate for you, considering the benefits and potential risks associated with its use.

  1. Bronchospasm: Anoro Ellipta should not be used as a rescue medication for treating acute episodes of bronchospasm. If sudden breathing difficulties or exacerbations occur, a fast-acting inhaler should be used. Contact your healthcare professional for guidance on managing acute symptoms.
  2. Cardiovascular Effects: Anoro Ellipta, like other medications containing LABAs, may cause an increase in heart rate and blood pressure. Individuals with a history of cardiovascular conditions should use Anoro Ellipta with caution and under the supervision of a healthcare professional.
  3. Worsening of Asthma: Anoro Ellipta is not indicated for the treatment of asthma. If you have asthma and are prescribed Anoro Ellipta, monitor your symptoms carefully. Inform your healthcare professional immediately if your asthma worsens or if you require more frequent use of your rescue inhaler.
  4. Paradoxical Bronchospasm: Anoro Ellipta may cause paradoxical bronchospasm, characterized by an immediate worsening of breathing difficulties. If this occurs, discontinue using Anoro Ellipta and seek medical attention promptly.
  5. Hypersensitivity Reactions: Hypersensitivity reactions, including rash, itching, swelling (especially of the face, lips, tongue, or throat), and difficulty breathing, have been reported with the use of Anoro Ellipta. Discontinue use and seek medical attention if any signs of a hypersensitivity reaction occur.
  6. Narrow-angle Glaucoma: Anoro Ellipta should be used with caution in individuals with narrow-angle glaucoma. It is important to inform your healthcare professional if you have a history of glaucoma or any changes in your vision while using Anoro Ellipta.
  7. Urinary Retention: Anoro Ellipta, as a LAMA medication, may cause urinary retention. Individuals with a history of urinary retention or bladder neck obstruction should use Anoro Ellipta with caution and under the guidance of a healthcare professional.
  8. Worsening of Ocular Conditions: Anoro Ellipta may exacerbate certain eye conditions, including narrow-angle glaucoma, cataracts, and increased intraocular pressure. Regular eye examinations are recommended for individuals using Anoro Ellipta, particularly those with a history of eye problems.
  9. Systemic Effects: Anoro Ellipta, like other medications containing corticosteroids, may have systemic effects. Prolonged use or high doses of corticosteroids can lead to adrenal suppression, Cushing’s syndrome, growth retardation in children, decreased bone mineral density, and other systemic effects. The dosage of corticosteroid in Anoro Ellipta is low, but it is still important to follow the prescribed dosing instructions and consult your healthcare professional for guidance.

Side Effects

Anoro Ellipta is a prescription medicine that contains a combination of two active ingredients: umeclidinium and vilanterol. It is primarily used as a long-term maintenance treatment for COPD, including chronic bronchitis and emphysema. Anoro Ellipta works by relaxing the muscles in the airways and improving breathing.

Common Side Effects

  1. Headache: One of the most common side effects reported by patients using Anoro Ellipta is a headache. This can occur due to the medication’s effect on blood vessels and changes in blood flow. The headache is usually mild and goes away on its own.
  2. Sore Throat: Some individuals may experience a sore throat after using Anoro Ellipta. This side effect is generally temporary and resolves without any specific treatment.
  3. Nasopharyngitis: Anoro Ellipta can sometimes cause inflammation of the nasal passages and the back of the throat, leading to symptoms such as a runny or stuffy nose and a sore throat.
  4. Cough: Coughing is another common side effect of Anoro Ellipta. It may occur due to the medication’s effect on the respiratory system. In most cases, the cough is not severe and subsides over time.
  5. Muscle Pain: Some individuals may experience muscle pain or muscle spasms while using Anoro Ellipta. This side effect is generally mild and temporary.

Rare Side Effects

  1. Allergic Reactions: Although rare, some individuals may develop an allergic reaction to Anoro Ellipta. Signs of an allergic reaction include hives, itching, rash, swelling of the face, lips, tongue, or throat, and difficulty breathing. If you experience any of these symptoms, seek immediate medical attention.
  2. Cardiovascular Effects: In rare cases, Anoro Ellipta may cause cardiovascular effects such as an increased heart rate, high blood pressure, or arrhythmias. If you have a history of cardiovascular problems, it is important to discuss the risks and benefits of using Anoro Ellipta with your healthcare provider.
  3. Paradoxical Bronchospasm: Paradoxical bronchospasm is a rare but potentially serious side effect of Anoro Ellipta. It causes the airways to narrow instead of opening them up, resulting in difficulty breathing. If you experience sudden wheezing, shortness of breath, or chest tightness after using Anoro Ellipta, seek immediate medical attention.
  4. Urinary Retention: Some individuals may experience difficulty urinating or a decreased urine flow while using Anoro Ellipta. If you have a history of urinary problems, it is important to inform your healthcare provider.
  5. Eye Problems: Rarely, Anoro Ellipta may cause eye problems such as narrow-angle glaucoma or blurred vision. If you experience any changes in your vision or eye discomfort while using this medication, consult your healthcare provider.

Usage

To ensure the safe and effective usage of Anoro Ellipta, it is important to follow the prescribed instructions provided by your healthcare professional. Here is a step-by-step guide on how to use Anoro Ellipta:

  1. Open the Inhaler: Hold the Ellipta inhaler in a horizontal position, with the cover facing upwards. Slide the cover down until you hear a “click” sound, indicating that the inhaler is ready for use.
  2. Breathe Out: Exhale fully, away from the inhaler, to ensure your lungs are empty before inhaling the medication.
  3. Inhale the Medication: Place your lips around the mouthpiece of the inhaler and take a steady, deep breath through your mouth. As you breathe in, the inhaler will release the medication as a fine powder. Continue to inhale steadily until your lungs are full.
  4. Hold Your Breath: After inhaling the medication, remove the inhaler from your mouth and hold your breath for about 5 to 10 seconds. This allows the medication to reach deep into your lungs.
  5. Exhale Slowly: Finally, exhale slowly and breathe normally.

It is important to clean the inhaler regularly and replace it as directed by your healthcare professional. If you have any difficulties or concerns about the usage of Anoro Ellipta, consult your healthcare provider for further guidance.

Dosage

To ensure the safe and effective use of Anoro Ellipta, it is crucial to follow the recommended dosage guidelines provided by healthcare professionals. The dosage may vary depending on individual factors such as age, severity of symptoms, and response to treatment. It is essential to consult a healthcare provider for personalized dosage instructions.

Here are some general dosage guidelines for Anoro Ellipta:

Starting Dosage

  1. The usual starting dosage for Anoro Ellipta is one inhalation per day.
  2. Each inhalation delivers a fixed dose of umeclidinium (62.5 mcg) and vilanterol (25 mcg).
  3. The inhalation should be taken at the same time every day to maintain consistent levels of medication in the body.

Maintenance Dosage

  1. After starting Anoro Ellipta, the maintenance dosage is usually one inhalation per day.
  2. The inhalation should be taken approximately 24 hours apart to maintain the desired therapeutic effect.

Maximum Dosage

  1. The maximum recommended dosage for Anoro Ellipta is one inhalation per day.
  2. Taking more than the prescribed dosage may increase the risk of side effects without providing additional benefits.

Missed Dosage

  1. If a dose of Anoro Ellipta is missed, it should be taken as soon as possible.
  2. However, if it is close to the time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed.
  3. Double dosing should be avoided to compensate for the missed dose.

Special Populations

  1. Elderly patients and those with liver or kidney impairment may require dosage adjustments.
  2. It is important to discuss individual circumstances with a healthcare provider for appropriate dosage recommendations.

Pregnancy

As with any medication, it is important to consider the potential risks and benefits before using Anoro Ellipta during pregnancy. While there is limited data on the use of Anoro Ellipta specifically in pregnant women, studies on animals have shown no evidence of harm to the fetus. However, animal studies may not always accurately predict the effects in humans.

It is not known whether Anoro Ellipta passes into breast milk. If you are breastfeeding or planning to breastfeed, discuss the potential risks and benefits with your healthcare provider. They will help you make an informed decision regarding the use of Anoro Ellipta while breastfeeding.

If you are pregnant or planning to become pregnant and rely on Anoro Ellipta for your respiratory health, it is crucial to consult your healthcare provider. They will assess your individual case and weigh the potential risks against the benefits of continuing or adjusting your medication during pregnancy. Your healthcare provider may consider alternative treatments or adjust the dosage of Anoro Ellipta to ensure the safety of both you and your baby.

Storage

Always keep Anoro Ellipta in its original packaging until you are ready to use it. The packaging is designed to protect the medication from light, moisture, and air, which can degrade its potency. If the packaging becomes damaged or torn, it is advisable to transfer the medication to a new container with the necessary labeling intact.

When storing Anoro Ellipta, ensure it is kept out of reach of children and pets. The medication should be stored in a secure location that is not easily accessible to curious hands or paws. Consider using childproof containers or cabinets to further enhance safety.

Anoro Ellipta should be shielded from direct sunlight or prolonged exposure to artificial light sources. Ultraviolet (UV) rays can degrade the medication’s active ingredients, rendering it less effective. Therefore, it is recommended to store Anoro Ellipta in a cool, dark place, such as a medicine cabinet or drawer.

It is essential to prevent Anoro Ellipta from freezing. Freezing temperatures can alter the medication’s composition and reduce its potency. If you accidentally freeze Anoro Ellipta, discard it and obtain a new supply from your healthcare provider or pharmacist.

Moisture can negatively impact the integrity of Anoro Ellipta. Store the medication in a dry environment, away from areas prone to humidity, such as the bathroom. Additionally, ensure your hands are clean and dry before handling the medication to avoid introducing moisture to the packaging.

High temperatures can compromise the effectiveness of Anoro Ellipta. Therefore, avoid storing the medication near heat sources such as radiators, stoves, or direct sunlight. Extreme heat can cause the medication to break down, reducing its therapeutic benefits.

It is crucial to store Anoro Ellipta in a secure location that is inaccessible to children. Accidental ingestion can be hazardous, and the medication should only be used under medical supervision. If a child accidentally consumes Anoro Ellipta, seek immediate medical attention.

Disposal

Before you begin the disposal process, make sure you have the following materials: an empty, sealable plastic bag, a sharps container (if applicable), a waste bin with a secure lid and gloves (optional, but recommended for added safety).

Look at the packaging of your Anora Ellipta medication to find the expiration date. If the medication is expired, do not use it and proceed to the disposal process.

Take the Anora Ellipta medication out of its packaging. Be careful not to touch the medication with bare hands, as it may cause skin irritation or transfer harmful substances.

Anora Ellipta comes in an inhaler device that contains a dose counter. Once the medication is finished or expired, you should dispose of the inhaler properly. Follow these steps:

  1. Hold the inhaler upright and open the cover.
  2. Push the lever away from you until it clicks.
  3. Close the cover of the inhaler.

 

Put the used or expired Anora Ellipta medication, along with the inhaler, inside a sealable plastic bag. This will prevent any potential leakage and keep the medication contained.

Close the sealable plastic bag tightly, ensuring that it is completely sealed. This will prevent any accidental exposure to the medication.

Place the sealed plastic bag containing the Anora Ellipta medication and inhaler in a waste bin with a secure lid. This will help prevent access by children, pets, or individuals who may accidentally come into contact with the medication.

If your Anora Ellipta inhaler contains sharps (e.g., needles), it is important to handle them with extra caution. Follow these steps to dispose of sharps safely:

  1. Place the used sharps in a designated sharps container.
  2. Seal the container tightly.
  3. Check local regulations for proper disposal methods of sharps containers. Some areas may have specific guidelines or collection sites for sharps disposal.

IMPORTANT NOTE: The information provided here is for educational purposes only and is not intended to serve as medical advice, diagnosis, or treatment recommendations. It should not be taken as an endorsement of any specific medication or treatment. Individual health conditions and responses to treatment can vary greatly; therefore, this information should not be seen as a guarantee of safety, suitability, or effectiveness for any particular individual. Always consult with a healthcare professional for personalized medical advice and before making any decisions regarding your health or treatment plans.

Product was successfully added to your cart!